GBIC Gulf Biomedical Corporation
GBIC -- Gulf Biomedical Corp.
Com (No Par)
1218 Autrey St.
Houston, TX 77006
Cold Laser Manufacturer and Vitamin Supplements (hair growth stimulants)
State of Incorporation: TX
Year of Incorporation 1988
Donald E. West, Pres. & Dir.; M.A. Ecclestone, Sec't. & Treasurer; M.C. Little, Dir.
Fiscal Year End: December 31
Edgar Filing Status: Non EDGAR Filer
Sedar Filing Status: Non SEDAR Filer
Outstanding Shares: 8,824,192 as of 2005-01-21
Estimated Market Cap: Not Available
Authorized Shares: 20,000,000 as of 2005-01-03
Float: 934,692 as of 2005-01-03
Number of Shareholders of Record: 362 as of
GBIC Contracts for Mass Production of Breakthrough HairMagic Product
Friday April 29, 5:19 pm ET
GBIC Stock Surges 400% on Strong Investor Interest and Positive Test Results
HOUSTON--(BUSINESS WIRE)--April 29, 2005--Gulf Biomedical Corporation (OTC: GBIC - News) is pleased to announce they have contracted with a major US nutriceutical manufacturer for the mass production of HairMagic(TM). HairMagic(TM) is a patented "breakthrough" hair restoration product which is anticipated to generate first year revenues of nearly $6 million. First year revenue was calculated by GBIC estimating over 100,000 HairMagic packets sold, priced at $59 per packet.
GBIC stock closed Friday at $0.21, up over 400% from 4 weeks ago.
Don West, President of GBIC stated, "Our goal is to implement an aggressive online sales campaign, seeking to generate a first-year income of almost $6 million." Mr. West continued to state, "The sales campaign follows the 100% success rate of HairMagic(TM). To date, we have provided an initial treatment to 70 hair loss victims. All 70 subjects treated reported experiencing the re-growth of new hair on their heads within four weeks. While the evidence is anecdotal, it is so strong and positive, that we have gained strong interest from consumers and shareholders."
For more information please contact President Donald E. West at 713-523-7539.
Disclaimer: This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of l995 relating to aspects of the Company's operations and strategies. Important factors could occur to cause actual results to differ materially from those described herein. There is a risk that the Company may incur losses. Readers are urged to consider these cautionary statements carefully. Forward-looking statements speak only as of the date of this news release, and the Company disclaims any obligations to update such statements.
Gulf Biomedical Corporation
Donald E. West, 713-522-2205